Viking Therapeutics Shares Face Mounting Pressure Amid Clinical and Financial Setbacks
Published on 09/14/2025 at 20:54 | Redaktion boerse-global.deViking Therapeutics finds itself navigating turbulent waters as its stock experiences a pronounced downward trajectory. Investor confidence has been significantly undermined by disappointing trial outcomes for a key drug candidate and a rapidly deteriorating financial position, firmly establishing the stock within a bearish trend.
The company’s financial health shows alarming signs of distress, compounding existing challenges. Recent figures reveal a substantial widening of losses, with the GAAP net loss for Q2 2025 reaching $65.6 million. This represents a dramatic increase compared to the $22.3 million loss reported during the same quarter last year. Market experts have responded by significantly revising their loss-per-share estimates upward for the 2025 fiscal year over the past two months.
Adding to market unease, CEO Brian Lian recently executed notable... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
